NCT04998136

Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity

Efficacy and Safety of Semaglutide 2.4 mg Once-weekly in Asians With Obesity Diagnosed as BMI ≥ 25 kg/m2 According to Local Guidelines

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 150 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study looks at how well semaglutide helps people lose weight. This study will look at the change in the participants' body weight from the start to the end of the study. The study compares the weight loss in people who get semaglutide to the weight loss in people who get placebo. Placebo is a "dummy" medicine that looks like the study medicine, but has no effect on the body. Participants will either get semaglutide or "dummy" medicine - which treatment participants get is decided by chance. Participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. Participants will also have talks with study staff about healthy food choices, how to be more physically active and what participants can do to lose weight. The study will last for about a year (50 weeks). Participants will have 10 clinic visits and 8 phone calls. At 6 of the clinic visits participants will have blood samples taken. Participants cannot take part if participants have or have had diabetes. Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period.

Conditions

• Obesity

Interventions

Type	Name	Description
DRUG	Semaglutide 2.4 mg	Administered subcutaneously (s.c., under the skin) as well as reduced-calorie diet and increased physical activity for 44 weeks. Doses gradually increased to 2.4 mg
DRUG	Placebo (semaglutide 2.4 mg)	Administered s.c. as well as reduced-calorie diet and increased physical activity for 44 weeks

Timeline

• Start date: 2022-08-15
• Primary completion: 2023-10-16
• Completion: 2023-11-20
• First posted: 2021-08-10
• Last updated: 2025-12-30
• Results posted: 2025-04-03

Locations

16 sites across 2 countries: South Korea, Thailand